Aion Therapeutic (AION) 주식 개요는 미국에서 건강 및 웰니스 사업을 영위하고 있습니다. 자세히 보기AION 펀더멘털 분석스노우플레이크 점수가치 평가1/6미래 성장0/6과거 실적0/6재무 건전성0/6배당0/6위험 분석주식은 유동성이 매우 낮습니다지난 5년간 매년 수익이 9.1% 감소했습니다.마이너스 주주 지분의미 있는 시가총액이 없습니다(CA$2M)+ 위험 2건 추가모든 위험 점검 보기AION Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW487,274 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG487,274 investors already sharing narrativesYour Fair ValueCA$Current PriceCA$0.00597.5% 저평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-19m43m2016201920222025202620282031Revenue CA$42.9mEarnings CA$6.3mAdvancedSet Fair ValueView all narrativesAion Therapeutic Inc. 경쟁사Silo WellnessSymbol: CNSX:SILOMarket cap: CA$1.5mGlow LifetechSymbol: CNSX:GLOWMarket cap: CA$8.7mSimply Solventless ConcentratesSymbol: TSXV:HASHMarket cap: CA$6.4mHerbal DispatchSymbol: CNSX:HERBMarket cap: CA$5.6m가격 이력 및 성과Aion Therapeutic 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가CA$0.00552주 최고가CA$0.01552주 최저가CA$0.005베타-0.491개월 변동0%3개월 변동0%1년 변동-66.67%3년 변동0%5년 변동-95.45%IPO 이후 변동-98.28%최근 뉴스 및 업데이트New Risk • Dec 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$1.3m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.3m free cash flow). Share price has been highly volatile over the past 3 months (48% average weekly change). Negative equity (-CA$4.1m). Earnings have declined by 8.7% per year over the past 5 years. Revenue is less than US$1m (CA$1.1m revenue, or US$798k). Market cap is less than US$10m (CA$4.84m market cap, or US$3.36m). Minor Risk Shareholders have been diluted in the past year (17% increase in shares outstanding).공시 • Oct 23Aion Therapeutic Inc. Announces Resignation of Larry Horwitz as DirectorAion Therapeutic Inc. announcing that Larry Horwitz resigned as a director effective October 18, 2024. The Company's board of directors currently consists of four directors.공시 • Oct 22Aion Therapeutic Inc. announced that it has received CAD 0.5 million in fundingAion Therapeutic Inc. announces that it intends to complete a non-brokered private placement offering of 33,333,333 units at a price of CAD 0.015 per unit for gross proceeds of CAD 500,000 on October 21, 2024. Each Unit will consist of one common share and one half of one common share purchase warrant. Each full Warrant will be exercisable to acquire one Share for a period of eighteen months following the closing of the Offering, at an exercise price of $0.05 per Warrant Share. All securities issued in connection with the Offering will be subject to a four month and one day hold as required under applicable securities laws.New Risk • Oct 20New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended January 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (54% average weekly change). Shareholders have been substantially diluted in the past year (135% increase in shares outstanding). Revenue is less than US$1m (CA$222k revenue, or US$161k). Market cap is less than US$10m (CA$7.46m market cap, or US$5.40m). Minor Risk Latest financial reports are more than 6 months old (reported January 2024 fiscal period end).공시 • Apr 23Aion Therapeutic Inc. announced that it expects to receive CAD 0.75 million in fundingAion Therapeutic Inc. announced a non-brokered private placement of up to 50,000,000 units at a price of CAD 0.015 per unit for total gross proceeds of up to CAD 750,000 on April 22, 2024. Each unit consists of one common share and one common share purchase warrant. Each warrant will be exercisable to acquire one share for a period of eighteen months following the closing of the offering, at an exercise price of CAD 0.05 per warrant share. All securities issued in connection with the offering will be subject to a four month and one day hold as required under applicable securities laws.Board Change • Dec 18Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Lead Independent Director Paul Crath was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.더 많은 업데이트 보기Recent updatesNew Risk • Dec 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$1.3m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.3m free cash flow). Share price has been highly volatile over the past 3 months (48% average weekly change). Negative equity (-CA$4.1m). Earnings have declined by 8.7% per year over the past 5 years. Revenue is less than US$1m (CA$1.1m revenue, or US$798k). Market cap is less than US$10m (CA$4.84m market cap, or US$3.36m). Minor Risk Shareholders have been diluted in the past year (17% increase in shares outstanding).공시 • Oct 23Aion Therapeutic Inc. Announces Resignation of Larry Horwitz as DirectorAion Therapeutic Inc. announcing that Larry Horwitz resigned as a director effective October 18, 2024. The Company's board of directors currently consists of four directors.공시 • Oct 22Aion Therapeutic Inc. announced that it has received CAD 0.5 million in fundingAion Therapeutic Inc. announces that it intends to complete a non-brokered private placement offering of 33,333,333 units at a price of CAD 0.015 per unit for gross proceeds of CAD 500,000 on October 21, 2024. Each Unit will consist of one common share and one half of one common share purchase warrant. Each full Warrant will be exercisable to acquire one Share for a period of eighteen months following the closing of the Offering, at an exercise price of $0.05 per Warrant Share. All securities issued in connection with the Offering will be subject to a four month and one day hold as required under applicable securities laws.New Risk • Oct 20New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended January 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (54% average weekly change). Shareholders have been substantially diluted in the past year (135% increase in shares outstanding). Revenue is less than US$1m (CA$222k revenue, or US$161k). Market cap is less than US$10m (CA$7.46m market cap, or US$5.40m). Minor Risk Latest financial reports are more than 6 months old (reported January 2024 fiscal period end).공시 • Apr 23Aion Therapeutic Inc. announced that it expects to receive CAD 0.75 million in fundingAion Therapeutic Inc. announced a non-brokered private placement of up to 50,000,000 units at a price of CAD 0.015 per unit for total gross proceeds of up to CAD 750,000 on April 22, 2024. Each unit consists of one common share and one common share purchase warrant. Each warrant will be exercisable to acquire one share for a period of eighteen months following the closing of the offering, at an exercise price of CAD 0.05 per warrant share. All securities issued in connection with the offering will be subject to a four month and one day hold as required under applicable securities laws.Board Change • Dec 18Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Lead Independent Director Paul Crath was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Oct 24Toppen Health Inc. entered into a definitive share purchase agreement to acquire Aion Therapeutic Inc. (CNSX:AION) for CAD 6.7 million in a reverse merger transaction.Toppen Health Inc. entered into a definitive share purchase agreement to acquire Aion Therapeutic Inc. (CNSX:AION) for CAD 6.7 million in a reverse merger transaction on October 10, 2023. The Purchase Consideration shall be satisfied through the issuance of 200,000,000 common shares in the capital of AION, to be issued at a deemed price of CAD 0.05 per share. AION may also be required to pay contingent consideration of $2,000,000 (CAD 2.74 million) if Toppen achieves revenue equal to or greater than $5,000,000 (CAD 6.84 million) for the period from October 18, 2023 to April 30, 2025. The completion of the Proposed Acquisition is subject to the successful completion of the Company’s due diligence review of Toppen, the approval of the Canadian Securities Exchange and other customary closing conditions. The completion of the Proposed Acquisition is currently expected to occur by the end of 2023.공시 • Oct 06Aion Therapeutic Inc. announced that it has received CAD 0.6425 million in fundingOn October 5, 2023, Aion Therapeutic Inc. closed the transaction. The company has issued 21,500,000 units at a price of CAD 0.01 per unit, for gross proceeds of CAD 215,000 in its second tranche closing. Including the first tranche of the unit offering, the company has issued a total of 64,250,000 units for total gross proceeds of CAD 642,500 in the transaction.Board Change • Sep 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Lead Independent Director Paul Crath was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.New Risk • Aug 17New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 29% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (87% average weekly change). Negative equity (-CA$1.9m). Earnings have declined by 2.7% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (CA$1.90m market cap, or US$1.40m). Minor Risk Shareholders have been diluted in the past year (29% increase in shares outstanding).공시 • Aug 15Aion Therapeutic Inc. announced that it has received CAD 0.4275 million in fundingOn August 14, 2023, Aion Therapeutic Inc. closed the transaction. The company issued 42,750,000 units at an issue price of CAD 0.01 per unit for the gross proceeds of CAD 427,500. Each Unit consists of one common share and one half of one common share purchase warrant. Each full Warrant is exercisable to acquire one Share for a period of eighteen months following the closing of the Unit Offering at an exercise price of CAD 0.10 per Warrant Share. All securities issued in connection with the Unit Offering are subject to a four month and one day hold as required under applicable securities laws.공시 • Jul 07Aion Therapeutic Announces Resignation of Rosy Mondin as DirectorAion Therapeutic Inc. announced that effective July 5, 2023, Rosy Mondin has resigned as a director of the Company.공시 • Jul 06Aion Therapeutic Inc. announced that it expects to receive CAD 0.5 million in fundingAion Therapeutic Inc announced a non-brokered private placement of up to 50,000,000 units at a price of CAD 0.01 per share for gross proceeds of up to CAD 500,000 on July 4, 2023. Each unit consisting of one common share and one-half of one common share purchase warrant. Each full warrant will be exercisable to acquire one share for a period of 18 months following the closing of the unit offering at an exercise price of CAD 0.1 per warrant share. The transaction is expected to close on or about July 31, 2023.Board Change • Nov 16High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Independent Director Sara Irwin is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.공시 • Jul 01Aion Therapeutic Inc. Announces Management and Board ChangesAion Therapeutic Inc. announced that Dr. Stephen D. Barnhill has resigned as a Director of Aion Therapeutic and Dr. Herbert Fritsche has resigned as Chief Science Officer of Aion Therapeutic, with both resignations effective June 30, 2022.Board Change • Apr 27High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. Independent Director Sara Irwin is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.공시 • Jun 12Aion Therapeutic Inc. announced that it has received CAD 1.487017 million in fundingAion Therapeutic Inc. (CNSX:AION) announced that it has received a non-brokered private placement of 16,994,475 units of the company at a price of CAD 0.0875 per unit to raise gross proceeds of CAD 1,487,016.56 on June 11, 2021. Each unit consists of one common share in the capital of the company and one half of one common share purchase warrant. Each warrant will entitle the holder, on exercise thereof, to purchase one additional common share at a price of CAD 0.15 for a period of 24 months from the closing of the transaction. The company has the right to accelerate the expiry date to be thirty days following written notice to the holders, if during the term of the warrants the common shares close at or above CAD 0.20 per common share on each trading day for a period of ten consecutive trading days on the Canadian Securities Exchange. The closing of the transaction is subject to all necessary regulatory approvals including acceptance from the TSX Venture Exchange. The company paid finder’s fees of CAD 20,874.24, in cash and 238,562 broker warrants. Each broker warrant entitles the holder thereof to acquire one common share at an exercise price of $0.15 per Common Share for a period of twenty-four months from the closing of the offering and subject to the acceleration provisions. All securities issued will be subject to a four-month plus one day hold period from the closing date under applicable Canadian securities laws.공시 • May 19Apollon and Aion Formulations Kill Breast Cancer Cells Through Multiple PathwaysApollon Formularies plc and Aion Therapeutic Inc. announced that joint testing has revealed their combined formulations to be effective in killing HER2+ breast cancer cells grown in 3D cell culture via three separate mechanisms: direct cell cytotoxicity, immune stimulated T-cell cytotoxicity, and macrophage induced phagocytosis. HER2-positive constitutes approximately 20% of all breast cancers. The testing was performed by BIOENSIS, an independent, pre-clinical predictive pharmaceutical testing laboratory. The medical cannabis formulations were developed by Apollon's affiliate, Apollon Formularies Jamaica Limited ("Apollon Jamaica"), and the medicinal mushroom formulations were developed by AI Pharmaceuticals Jamaica Limited ("AI Pharma"), a subsidiary of Aion. The testing results showed that Apollon Jamaica's medical cannabis formulations were particularly effective in killing living HER2+ cancer cells directly (direct cytotoxicity), while Aion's medicinal mushroom formulations were most effective in stimulating the immune system's T-cell production to attack and kill HER2+ cancer cells and through macrophage induced phagocytosis. When the two formulations were combined, nearly 100% of HER2+ breast cancer cells in 3D cell cultures were killed through the three different pathways. The testing occurred as a part of a Joint Testing Agreement between the parties and was authorized in accordance with Apollon Jamaica's Research & Development licence issued by the Jamaican government's Cannabis Licensing Authority (CLA). In the performance of services under the Joint Testing Agreement, each party confined its activities to those permitted by applicable law, with CLA licensed Apollon Jamaica performing medical cannabis activities and AI Pharma performing services involving functional medicinal mushrooms. Mushroom formulations containing psilocybin or psilocin, which comes from psychedelic mushrooms, were not included as a part of the joint testing. AI Pharma currently has an agreement with Apollon Jamaica to license equipment and an agreement with Doc's Place International Inc. to sublease space in order that AI Pharma can perform cultivation, research and development, processing and treatment services in Jamaica with regard to its medicinal mushrooms formulations. The companies next expect to negotiate a joint license agreement involving their formulations and intellectual property whereby AI Pharma may exclusively use Apollon Jamaica's medical cannabis formulations in their combined product lines in the US and Canada, and Apollon may exclusively use certain of Aion's medicinal (non-psilocybin) mushroom products in their combined product lines in Europe and Jamaica, where legal. This structure would allow Apollon to benefit from Aion's sales in the US and Canada, where Apollon Jamaica is unable to sell medical cannabis under current US and UK law. In both instances, medical care will be done by physicians and psychiatrists authorized to prescribe medications and treat patients.공시 • Mar 12Aion Therapeutic Inc. Files 4 New Patent Applications (Including for the Treatment of Human Cancers)Aion Therapeutic Inc. announced that it has filed 4 new patent applications related to preparations of medicinal and psychedelic mushrooms. The patent applications include use of medicinal mushrooms for the treatment of human cancers including breast cancer, use of combination medical cannabis and medicinal mushroom preparations for the treatment of interstitial cystitis and other bladder diseases, and methods for producing emulsions and nano-emulsions for increasing bioavailability in these formulations. These new additions increase intellectual property portfolio to a current total of 9 patent applications with more expected in the very near future.공시 • Feb 24+ 1 more updateAion Therapeutic Hires Winston De La Haye as Medical DirectorAion Therapeutic Inc. announced the opening of the Aion International Center for Psychedelic Psychiatry in Jamaica. The Center will initially specialize in the use of psilocybin for the treatment of addiction (tobacco, alcohol, and other drug misuse), depression and anxiety associated with life-threatening illnesses, treatment-resistant depression, and major depressive disorder (MDD). In addition, the Center will be studying the effectiveness of psilocybin as a new therapy for opioid addiction, Alzheimer's disease, post- traumatic stress disorder (PTSD), and anorexia nervosa. The Medical Director of the Aion International Center for Psychedelic Psychiatry is Winston De La Haye, M.D., M.P.H, D.M., I.C.A.P. Dr. De La Haye is Deputy Dean in the Faculty of Medical Sciences, The University of the West Indies (UWI), Mona, Jamaica and a Consultant General and Addiction Psychiatrist at the University Hospital of the West Indies (UHWI). He completed his MD (Cum Laude) at the University of Pecs in Hungary, his Postgraduate Degree in Psychiatry at the UWI, his Masters in Public Health (Cum Laude) and a Fulbright Fellowship in Substance Abuse at the Johns Hopkins University (JHU). He is an Internationally Certified Addiction Professional and a Global Master Trainer of Trainers in the Treatment of Substance Use Disorders.Executive Departure • Feb 06President James W. Thompson has left the companyOn the 2nd of February, James W. Thompson's tenure as President ended after less than a year in the role. We don't have any record of a personal shareholding under James W.'s name. A total of 3 executives have left over the last 12 months.공시 • Feb 04Aion Therapeutic Inc Announces Resignation of James Thompson as PresidentAion Therapeutic Inc. announced the resignation of Dr. James Thompson as President, effective February 2, 2021. Dr. Thompson tendered his resignation to accept a senior bio-medical advisor role with one of Aion Therapeutic’s institutional investors which will allow him to continue to support the development of the Company.공시 • Dec 24Aion Therapeutic Inc. announced that it has received CAD 1 million in fundingAion Therapeutic Inc. (CNSX:AION) announced a non-brokered private placement of 15,384,615 units at CAD 0.065 per unit for gross proceeds of CAD 1,000,000 on December 23, 2020. Each unit consists of one common share and one half of one common share purchase warrant. Each warrant entitles the holder to purchase one share of the company at CAD 0.15 per share for twenty four months from closing. Furthermore, the company has the right to accelerate the expiry date to be thirty days following written notice to the holders, if during the term of the warrants the common shares close at or above CAD 0.20 per common share on each trading day for a period of ten consecutive trading days on the Canadian Securities Exchange. The completion of the transaction is subject to certain closing conditions including, but not limited to, the receipt of all necessary regulatory and other approvals including the final approval of the Canadian Securities Exchange. All securities issued in connection with the transaction will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation.공시 • Sep 21Aion Therapeutic Inc. announced that it has received CAD 0.5 million in fundingAion Therapeutic Inc. (CNSX:AION) announced the closing of a non-brokered private placement of 9,090,907 units at a price of CAD 0.055 per unit for gross proceeds of up to CAD 499,999.885 on September 18, 2020. Each unit consists of one common share and one-half of one common share purchase warrant. Each full warrant entitles the holder to acquire one additional common share for a period of 24 months from date of issuance at an exercise price of CAD 0.15 per common share. The company has the right to accelerate the expiry date to be 30 days following written notice to the holders, if during the term of the warrants the common shares close at or above CAD 0.20 per common share on each trading day for a period of ten consecutive trading days on the Canadian Securities Exchange. All securities sold under the transaction will be subject to a statutory four month and one day hold period.공시 • Aug 07Osoyoos Cannabis Inc. announced that it has received CAD 1.010417 million in funding from Cannabis Growth Opportunity CorporationOn July 31, 2020, Osoyoos Cannabis Inc. (CNSX:OSO) closed the transaction. The company has issued 20,208,340 units for gross proceeds of CAD 1,010,417 in the transaction. The company issued 10,208,340 units for gross proceeds of CAD 510,417 in its third and final tranche.공시 • Jul 18Osoyoos Cannabis Inc. Auditor Raises 'Going Concern' DoubtOsoyoos Cannabis Inc. filed its Annual on Jul 10, 2020 for the period ending Apr 30, 2020. In this report its auditor, Buckley Dodds, gave an unqualified opinion expressing doubt that the company can continue as a going concern.공시 • Jun 29Osoyoos Cannabis Inc. (CNSX:OSO) entered into a share purchase agreement to acquire 1196691 B.C. Ltd. for CAD 2.5 million.Osoyoos Cannabis Inc. (CNSX:OSO) entered into a share purchase agreement to acquire 1196691 B.C. Ltd. for CAD 2.5 million on June 26, 2020. As part of the consideration Osoyoos Cannabis Inc. will issue 36 million shares to 1196691 B.C. Ltd. at a deemed price of $0.07 per share. The transaction is expected to close on or around June 30, 2020.공시 • Jun 18Osoyoos Cannabis Inc. announced that it expects to receive CAD 1 million in fundingOsoyoos Cannabis Inc. (CNSX:OSO) announced that it has entered into subscription agreement for non-brokered private placement of up to 20,000,000 units at a price of CAD 0.05 per unit for gross proceeds of up to CAD 1,000,000 on June 8, 2020. Each unit consists of one common share and one-half of one common share purchase warrant. Each full warrant entitles the holder to acquire one additional common share for a period of 24 months from date of issuance at an exercise price of CAD 0.15 per common share. The company will have the right to accelerate the expiry date to be 30 days following written notice to the holders, if during the term of the warrants the common shares close at or above cad 0.20 per common share on each trading day for a period of ten consecutive trading days on the Canadian Securities Exchange. All securities sold under the transaction will be subject to a statutory four month and one day hold period. The transaction will include participation from a Canadian institutional investor. The company will raise funding in tranche, initial tranche of CAD 75,000 will be completed within 10 days and the remaining CAD 925,000 will be received in two additional equal tranches within 10 days of the company achieving mutually agreed corporate milestones. The Institutional Investor will be entitled to deduct from its commitment an amount equal to the aggregate gross proceeds.공시 • Jun 17Osoyoos Cannabis Inc. announced that it expects to receive CAD 1 million in fundingOsoyoos Cannabis Inc. (CNSX:OSO) announced a non-brokered private placement of up to 20,000,000 units, at a price of CAD 0.05 per unit, for gross proceeds of up to CAD 1,000,000 on June 16, 2020. Each unit will consist of one common share of the company and one-half of one common share purchase warrant of the company. Each full warrant will entitle the holder to acquire one additional common share for a period of 24 months from the date of issuance at a price of CAD 0.15 per common share. The company will have the right to accelerate the expiry date to be 30 days following written notice to the holders, if during the term of the warrants the common shares close at or above cad 0.20 per common share on each trading day for a period of ten consecutive trading days on the Canadian Securities Exchange. All securities sold under the transaction will be subject to a statutory four month and one day hold period. On the same date, the company announced that it has issued 1,500,000 units for gross proceeds of CAD 75,000 in first tranche of the transaction.주주 수익률AIONCA PharmaceuticalsCA 시장7D0%-5.2%0.5%1Y-66.7%29.3%28.5%전체 주주 수익률 보기수익률 대 산업: AION은 지난 1년 동안 29.3%의 수익을 기록한 Canadian Pharmaceuticals 산업보다 저조한 성과를 냈습니다.수익률 대 시장: AION은 지난 1년 동안 28.5%를 기록한 Canadian 시장보다 저조한 성과를 냈습니다.주가 변동성Is AION's price volatile compared to industry and market?AION volatilityAION Average Weekly Movementn/aPharmaceuticals Industry Average Movement10.1%Market Average Movement9.6%10% most volatile stocks in CA Market16.5%10% least volatile stocks in CA Market3.7%안정적인 주가: AION의 주가는 지난 3개월 동안 Canadian 시장보다 변동성이 컸습니다.시간에 따른 변동성: Insufficient data to determine AION의 변동성 변화를 판단할 수 없습니다.회사 소개설립직원 수CEO웹사이트2011n/aJohn Simmondsn/a는 미국에서 건강 및 웰니스 사업을 영위하고 있습니다. 이 회사는 이전에 오소요스 대마초 주식회사로 알려졌으며 2020년 8월에 아이온 테라퓨틱 주식회사로 사명을 변경했습니다. 는 2011년에 설립되었으며 캐나다 밴쿠버에 본사를 두고 있습니다.더 보기Aion Therapeutic Inc. 기초 지표 요약Aion Therapeutic의 순이익과 매출은 시가총액과 어떻게 비교됩니까?AION 기초 통계시가총액CA$2.49m순이익 (TTM)-CA$6.65m매출 (TTM)CA$1.47m1.7x주가매출비율(P/S)-0.4x주가수익비율(P/E)AION는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표AION 손익계산서 (TTM)매출CA$1.47m매출원가CA$997.32k총이익CA$475.59k기타 비용CA$7.12m순이익-CA$6.65m최근 보고된 실적Jan 31, 2025다음 실적 발표일해당 없음주당순이익(EPS)-0.013총이익률32.29%순이익률-451.18%부채/자본 비율-60.1%AION의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/12/03 04:01종가2025/09/05 00:00수익2025/01/31연간 수익2024/04/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Aion Therapeutic Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
New Risk • Dec 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$1.3m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.3m free cash flow). Share price has been highly volatile over the past 3 months (48% average weekly change). Negative equity (-CA$4.1m). Earnings have declined by 8.7% per year over the past 5 years. Revenue is less than US$1m (CA$1.1m revenue, or US$798k). Market cap is less than US$10m (CA$4.84m market cap, or US$3.36m). Minor Risk Shareholders have been diluted in the past year (17% increase in shares outstanding).
공시 • Oct 23Aion Therapeutic Inc. Announces Resignation of Larry Horwitz as DirectorAion Therapeutic Inc. announcing that Larry Horwitz resigned as a director effective October 18, 2024. The Company's board of directors currently consists of four directors.
공시 • Oct 22Aion Therapeutic Inc. announced that it has received CAD 0.5 million in fundingAion Therapeutic Inc. announces that it intends to complete a non-brokered private placement offering of 33,333,333 units at a price of CAD 0.015 per unit for gross proceeds of CAD 500,000 on October 21, 2024. Each Unit will consist of one common share and one half of one common share purchase warrant. Each full Warrant will be exercisable to acquire one Share for a period of eighteen months following the closing of the Offering, at an exercise price of $0.05 per Warrant Share. All securities issued in connection with the Offering will be subject to a four month and one day hold as required under applicable securities laws.
New Risk • Oct 20New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended January 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (54% average weekly change). Shareholders have been substantially diluted in the past year (135% increase in shares outstanding). Revenue is less than US$1m (CA$222k revenue, or US$161k). Market cap is less than US$10m (CA$7.46m market cap, or US$5.40m). Minor Risk Latest financial reports are more than 6 months old (reported January 2024 fiscal period end).
공시 • Apr 23Aion Therapeutic Inc. announced that it expects to receive CAD 0.75 million in fundingAion Therapeutic Inc. announced a non-brokered private placement of up to 50,000,000 units at a price of CAD 0.015 per unit for total gross proceeds of up to CAD 750,000 on April 22, 2024. Each unit consists of one common share and one common share purchase warrant. Each warrant will be exercisable to acquire one share for a period of eighteen months following the closing of the offering, at an exercise price of CAD 0.05 per warrant share. All securities issued in connection with the offering will be subject to a four month and one day hold as required under applicable securities laws.
Board Change • Dec 18Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Lead Independent Director Paul Crath was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
New Risk • Dec 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$1.3m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.3m free cash flow). Share price has been highly volatile over the past 3 months (48% average weekly change). Negative equity (-CA$4.1m). Earnings have declined by 8.7% per year over the past 5 years. Revenue is less than US$1m (CA$1.1m revenue, or US$798k). Market cap is less than US$10m (CA$4.84m market cap, or US$3.36m). Minor Risk Shareholders have been diluted in the past year (17% increase in shares outstanding).
공시 • Oct 23Aion Therapeutic Inc. Announces Resignation of Larry Horwitz as DirectorAion Therapeutic Inc. announcing that Larry Horwitz resigned as a director effective October 18, 2024. The Company's board of directors currently consists of four directors.
공시 • Oct 22Aion Therapeutic Inc. announced that it has received CAD 0.5 million in fundingAion Therapeutic Inc. announces that it intends to complete a non-brokered private placement offering of 33,333,333 units at a price of CAD 0.015 per unit for gross proceeds of CAD 500,000 on October 21, 2024. Each Unit will consist of one common share and one half of one common share purchase warrant. Each full Warrant will be exercisable to acquire one Share for a period of eighteen months following the closing of the Offering, at an exercise price of $0.05 per Warrant Share. All securities issued in connection with the Offering will be subject to a four month and one day hold as required under applicable securities laws.
New Risk • Oct 20New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended January 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (54% average weekly change). Shareholders have been substantially diluted in the past year (135% increase in shares outstanding). Revenue is less than US$1m (CA$222k revenue, or US$161k). Market cap is less than US$10m (CA$7.46m market cap, or US$5.40m). Minor Risk Latest financial reports are more than 6 months old (reported January 2024 fiscal period end).
공시 • Apr 23Aion Therapeutic Inc. announced that it expects to receive CAD 0.75 million in fundingAion Therapeutic Inc. announced a non-brokered private placement of up to 50,000,000 units at a price of CAD 0.015 per unit for total gross proceeds of up to CAD 750,000 on April 22, 2024. Each unit consists of one common share and one common share purchase warrant. Each warrant will be exercisable to acquire one share for a period of eighteen months following the closing of the offering, at an exercise price of CAD 0.05 per warrant share. All securities issued in connection with the offering will be subject to a four month and one day hold as required under applicable securities laws.
Board Change • Dec 18Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Lead Independent Director Paul Crath was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Oct 24Toppen Health Inc. entered into a definitive share purchase agreement to acquire Aion Therapeutic Inc. (CNSX:AION) for CAD 6.7 million in a reverse merger transaction.Toppen Health Inc. entered into a definitive share purchase agreement to acquire Aion Therapeutic Inc. (CNSX:AION) for CAD 6.7 million in a reverse merger transaction on October 10, 2023. The Purchase Consideration shall be satisfied through the issuance of 200,000,000 common shares in the capital of AION, to be issued at a deemed price of CAD 0.05 per share. AION may also be required to pay contingent consideration of $2,000,000 (CAD 2.74 million) if Toppen achieves revenue equal to or greater than $5,000,000 (CAD 6.84 million) for the period from October 18, 2023 to April 30, 2025. The completion of the Proposed Acquisition is subject to the successful completion of the Company’s due diligence review of Toppen, the approval of the Canadian Securities Exchange and other customary closing conditions. The completion of the Proposed Acquisition is currently expected to occur by the end of 2023.
공시 • Oct 06Aion Therapeutic Inc. announced that it has received CAD 0.6425 million in fundingOn October 5, 2023, Aion Therapeutic Inc. closed the transaction. The company has issued 21,500,000 units at a price of CAD 0.01 per unit, for gross proceeds of CAD 215,000 in its second tranche closing. Including the first tranche of the unit offering, the company has issued a total of 64,250,000 units for total gross proceeds of CAD 642,500 in the transaction.
Board Change • Sep 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Lead Independent Director Paul Crath was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
New Risk • Aug 17New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 29% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (87% average weekly change). Negative equity (-CA$1.9m). Earnings have declined by 2.7% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (CA$1.90m market cap, or US$1.40m). Minor Risk Shareholders have been diluted in the past year (29% increase in shares outstanding).
공시 • Aug 15Aion Therapeutic Inc. announced that it has received CAD 0.4275 million in fundingOn August 14, 2023, Aion Therapeutic Inc. closed the transaction. The company issued 42,750,000 units at an issue price of CAD 0.01 per unit for the gross proceeds of CAD 427,500. Each Unit consists of one common share and one half of one common share purchase warrant. Each full Warrant is exercisable to acquire one Share for a period of eighteen months following the closing of the Unit Offering at an exercise price of CAD 0.10 per Warrant Share. All securities issued in connection with the Unit Offering are subject to a four month and one day hold as required under applicable securities laws.
공시 • Jul 07Aion Therapeutic Announces Resignation of Rosy Mondin as DirectorAion Therapeutic Inc. announced that effective July 5, 2023, Rosy Mondin has resigned as a director of the Company.
공시 • Jul 06Aion Therapeutic Inc. announced that it expects to receive CAD 0.5 million in fundingAion Therapeutic Inc announced a non-brokered private placement of up to 50,000,000 units at a price of CAD 0.01 per share for gross proceeds of up to CAD 500,000 on July 4, 2023. Each unit consisting of one common share and one-half of one common share purchase warrant. Each full warrant will be exercisable to acquire one share for a period of 18 months following the closing of the unit offering at an exercise price of CAD 0.1 per warrant share. The transaction is expected to close on or about July 31, 2023.
Board Change • Nov 16High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Independent Director Sara Irwin is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
공시 • Jul 01Aion Therapeutic Inc. Announces Management and Board ChangesAion Therapeutic Inc. announced that Dr. Stephen D. Barnhill has resigned as a Director of Aion Therapeutic and Dr. Herbert Fritsche has resigned as Chief Science Officer of Aion Therapeutic, with both resignations effective June 30, 2022.
Board Change • Apr 27High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. Independent Director Sara Irwin is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
공시 • Jun 12Aion Therapeutic Inc. announced that it has received CAD 1.487017 million in fundingAion Therapeutic Inc. (CNSX:AION) announced that it has received a non-brokered private placement of 16,994,475 units of the company at a price of CAD 0.0875 per unit to raise gross proceeds of CAD 1,487,016.56 on June 11, 2021. Each unit consists of one common share in the capital of the company and one half of one common share purchase warrant. Each warrant will entitle the holder, on exercise thereof, to purchase one additional common share at a price of CAD 0.15 for a period of 24 months from the closing of the transaction. The company has the right to accelerate the expiry date to be thirty days following written notice to the holders, if during the term of the warrants the common shares close at or above CAD 0.20 per common share on each trading day for a period of ten consecutive trading days on the Canadian Securities Exchange. The closing of the transaction is subject to all necessary regulatory approvals including acceptance from the TSX Venture Exchange. The company paid finder’s fees of CAD 20,874.24, in cash and 238,562 broker warrants. Each broker warrant entitles the holder thereof to acquire one common share at an exercise price of $0.15 per Common Share for a period of twenty-four months from the closing of the offering and subject to the acceleration provisions. All securities issued will be subject to a four-month plus one day hold period from the closing date under applicable Canadian securities laws.
공시 • May 19Apollon and Aion Formulations Kill Breast Cancer Cells Through Multiple PathwaysApollon Formularies plc and Aion Therapeutic Inc. announced that joint testing has revealed their combined formulations to be effective in killing HER2+ breast cancer cells grown in 3D cell culture via three separate mechanisms: direct cell cytotoxicity, immune stimulated T-cell cytotoxicity, and macrophage induced phagocytosis. HER2-positive constitutes approximately 20% of all breast cancers. The testing was performed by BIOENSIS, an independent, pre-clinical predictive pharmaceutical testing laboratory. The medical cannabis formulations were developed by Apollon's affiliate, Apollon Formularies Jamaica Limited ("Apollon Jamaica"), and the medicinal mushroom formulations were developed by AI Pharmaceuticals Jamaica Limited ("AI Pharma"), a subsidiary of Aion. The testing results showed that Apollon Jamaica's medical cannabis formulations were particularly effective in killing living HER2+ cancer cells directly (direct cytotoxicity), while Aion's medicinal mushroom formulations were most effective in stimulating the immune system's T-cell production to attack and kill HER2+ cancer cells and through macrophage induced phagocytosis. When the two formulations were combined, nearly 100% of HER2+ breast cancer cells in 3D cell cultures were killed through the three different pathways. The testing occurred as a part of a Joint Testing Agreement between the parties and was authorized in accordance with Apollon Jamaica's Research & Development licence issued by the Jamaican government's Cannabis Licensing Authority (CLA). In the performance of services under the Joint Testing Agreement, each party confined its activities to those permitted by applicable law, with CLA licensed Apollon Jamaica performing medical cannabis activities and AI Pharma performing services involving functional medicinal mushrooms. Mushroom formulations containing psilocybin or psilocin, which comes from psychedelic mushrooms, were not included as a part of the joint testing. AI Pharma currently has an agreement with Apollon Jamaica to license equipment and an agreement with Doc's Place International Inc. to sublease space in order that AI Pharma can perform cultivation, research and development, processing and treatment services in Jamaica with regard to its medicinal mushrooms formulations. The companies next expect to negotiate a joint license agreement involving their formulations and intellectual property whereby AI Pharma may exclusively use Apollon Jamaica's medical cannabis formulations in their combined product lines in the US and Canada, and Apollon may exclusively use certain of Aion's medicinal (non-psilocybin) mushroom products in their combined product lines in Europe and Jamaica, where legal. This structure would allow Apollon to benefit from Aion's sales in the US and Canada, where Apollon Jamaica is unable to sell medical cannabis under current US and UK law. In both instances, medical care will be done by physicians and psychiatrists authorized to prescribe medications and treat patients.
공시 • Mar 12Aion Therapeutic Inc. Files 4 New Patent Applications (Including for the Treatment of Human Cancers)Aion Therapeutic Inc. announced that it has filed 4 new patent applications related to preparations of medicinal and psychedelic mushrooms. The patent applications include use of medicinal mushrooms for the treatment of human cancers including breast cancer, use of combination medical cannabis and medicinal mushroom preparations for the treatment of interstitial cystitis and other bladder diseases, and methods for producing emulsions and nano-emulsions for increasing bioavailability in these formulations. These new additions increase intellectual property portfolio to a current total of 9 patent applications with more expected in the very near future.
공시 • Feb 24+ 1 more updateAion Therapeutic Hires Winston De La Haye as Medical DirectorAion Therapeutic Inc. announced the opening of the Aion International Center for Psychedelic Psychiatry in Jamaica. The Center will initially specialize in the use of psilocybin for the treatment of addiction (tobacco, alcohol, and other drug misuse), depression and anxiety associated with life-threatening illnesses, treatment-resistant depression, and major depressive disorder (MDD). In addition, the Center will be studying the effectiveness of psilocybin as a new therapy for opioid addiction, Alzheimer's disease, post- traumatic stress disorder (PTSD), and anorexia nervosa. The Medical Director of the Aion International Center for Psychedelic Psychiatry is Winston De La Haye, M.D., M.P.H, D.M., I.C.A.P. Dr. De La Haye is Deputy Dean in the Faculty of Medical Sciences, The University of the West Indies (UWI), Mona, Jamaica and a Consultant General and Addiction Psychiatrist at the University Hospital of the West Indies (UHWI). He completed his MD (Cum Laude) at the University of Pecs in Hungary, his Postgraduate Degree in Psychiatry at the UWI, his Masters in Public Health (Cum Laude) and a Fulbright Fellowship in Substance Abuse at the Johns Hopkins University (JHU). He is an Internationally Certified Addiction Professional and a Global Master Trainer of Trainers in the Treatment of Substance Use Disorders.
Executive Departure • Feb 06President James W. Thompson has left the companyOn the 2nd of February, James W. Thompson's tenure as President ended after less than a year in the role. We don't have any record of a personal shareholding under James W.'s name. A total of 3 executives have left over the last 12 months.
공시 • Feb 04Aion Therapeutic Inc Announces Resignation of James Thompson as PresidentAion Therapeutic Inc. announced the resignation of Dr. James Thompson as President, effective February 2, 2021. Dr. Thompson tendered his resignation to accept a senior bio-medical advisor role with one of Aion Therapeutic’s institutional investors which will allow him to continue to support the development of the Company.
공시 • Dec 24Aion Therapeutic Inc. announced that it has received CAD 1 million in fundingAion Therapeutic Inc. (CNSX:AION) announced a non-brokered private placement of 15,384,615 units at CAD 0.065 per unit for gross proceeds of CAD 1,000,000 on December 23, 2020. Each unit consists of one common share and one half of one common share purchase warrant. Each warrant entitles the holder to purchase one share of the company at CAD 0.15 per share for twenty four months from closing. Furthermore, the company has the right to accelerate the expiry date to be thirty days following written notice to the holders, if during the term of the warrants the common shares close at or above CAD 0.20 per common share on each trading day for a period of ten consecutive trading days on the Canadian Securities Exchange. The completion of the transaction is subject to certain closing conditions including, but not limited to, the receipt of all necessary regulatory and other approvals including the final approval of the Canadian Securities Exchange. All securities issued in connection with the transaction will be subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation.
공시 • Sep 21Aion Therapeutic Inc. announced that it has received CAD 0.5 million in fundingAion Therapeutic Inc. (CNSX:AION) announced the closing of a non-brokered private placement of 9,090,907 units at a price of CAD 0.055 per unit for gross proceeds of up to CAD 499,999.885 on September 18, 2020. Each unit consists of one common share and one-half of one common share purchase warrant. Each full warrant entitles the holder to acquire one additional common share for a period of 24 months from date of issuance at an exercise price of CAD 0.15 per common share. The company has the right to accelerate the expiry date to be 30 days following written notice to the holders, if during the term of the warrants the common shares close at or above CAD 0.20 per common share on each trading day for a period of ten consecutive trading days on the Canadian Securities Exchange. All securities sold under the transaction will be subject to a statutory four month and one day hold period.
공시 • Aug 07Osoyoos Cannabis Inc. announced that it has received CAD 1.010417 million in funding from Cannabis Growth Opportunity CorporationOn July 31, 2020, Osoyoos Cannabis Inc. (CNSX:OSO) closed the transaction. The company has issued 20,208,340 units for gross proceeds of CAD 1,010,417 in the transaction. The company issued 10,208,340 units for gross proceeds of CAD 510,417 in its third and final tranche.
공시 • Jul 18Osoyoos Cannabis Inc. Auditor Raises 'Going Concern' DoubtOsoyoos Cannabis Inc. filed its Annual on Jul 10, 2020 for the period ending Apr 30, 2020. In this report its auditor, Buckley Dodds, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
공시 • Jun 29Osoyoos Cannabis Inc. (CNSX:OSO) entered into a share purchase agreement to acquire 1196691 B.C. Ltd. for CAD 2.5 million.Osoyoos Cannabis Inc. (CNSX:OSO) entered into a share purchase agreement to acquire 1196691 B.C. Ltd. for CAD 2.5 million on June 26, 2020. As part of the consideration Osoyoos Cannabis Inc. will issue 36 million shares to 1196691 B.C. Ltd. at a deemed price of $0.07 per share. The transaction is expected to close on or around June 30, 2020.
공시 • Jun 18Osoyoos Cannabis Inc. announced that it expects to receive CAD 1 million in fundingOsoyoos Cannabis Inc. (CNSX:OSO) announced that it has entered into subscription agreement for non-brokered private placement of up to 20,000,000 units at a price of CAD 0.05 per unit for gross proceeds of up to CAD 1,000,000 on June 8, 2020. Each unit consists of one common share and one-half of one common share purchase warrant. Each full warrant entitles the holder to acquire one additional common share for a period of 24 months from date of issuance at an exercise price of CAD 0.15 per common share. The company will have the right to accelerate the expiry date to be 30 days following written notice to the holders, if during the term of the warrants the common shares close at or above cad 0.20 per common share on each trading day for a period of ten consecutive trading days on the Canadian Securities Exchange. All securities sold under the transaction will be subject to a statutory four month and one day hold period. The transaction will include participation from a Canadian institutional investor. The company will raise funding in tranche, initial tranche of CAD 75,000 will be completed within 10 days and the remaining CAD 925,000 will be received in two additional equal tranches within 10 days of the company achieving mutually agreed corporate milestones. The Institutional Investor will be entitled to deduct from its commitment an amount equal to the aggregate gross proceeds.
공시 • Jun 17Osoyoos Cannabis Inc. announced that it expects to receive CAD 1 million in fundingOsoyoos Cannabis Inc. (CNSX:OSO) announced a non-brokered private placement of up to 20,000,000 units, at a price of CAD 0.05 per unit, for gross proceeds of up to CAD 1,000,000 on June 16, 2020. Each unit will consist of one common share of the company and one-half of one common share purchase warrant of the company. Each full warrant will entitle the holder to acquire one additional common share for a period of 24 months from the date of issuance at a price of CAD 0.15 per common share. The company will have the right to accelerate the expiry date to be 30 days following written notice to the holders, if during the term of the warrants the common shares close at or above cad 0.20 per common share on each trading day for a period of ten consecutive trading days on the Canadian Securities Exchange. All securities sold under the transaction will be subject to a statutory four month and one day hold period. On the same date, the company announced that it has issued 1,500,000 units for gross proceeds of CAD 75,000 in first tranche of the transaction.
